Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus

  title={Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus},
  author={Kateřina Venderov{\'a} and Timothy Matthew Brown and Jonathan M. Brotchie},
  journal={Experimental Neurology},

Cannabinoid Agonists Stimulate [3H]GABA Release in the Globus Pallidus of the Rat When Gi Protein-Receptor Coupling Is Restricted: Role of Dopamine D2 Receptors

CB1 receptor activation has dual effects on GABA release in the globus pallidus through mechanisms that are independent of D2 receptor activation, which is consistent with the proposal that D2 receptors reduce Gi/o proteins available for binding to the CB1 receptor.

Endocannabinoids in basal ganglia circuits

Some basic concepts on the biochemistry, pharmacology, and synaptic modulatory role of the endocannabinoid system with focus on the basal ganglia circuits, and the potential implications for Parkinson disease (PD) are reviewed.

Homeostatic changes of the endocannabinoid system in Parkinson's disease

Endocannabinoids (eCBs) are endogenous lipids that bind principally type‐1 and type‐2 cannabinoid (CB1 and CB2) receptors. N‐Arachidonoylethanolamine (AEA, anandamide) and 2‐arachidonoylglycerol

The emerging role of the endocannabinoid system in the sleep-wake cycle modulation.

This review will focus on some of the current evidence of the pharmacological potential of the endocannabinoid system on sleep modulation and the role of fatty acid amide hydrolase and monoacylglycerol lipase in the metabolism of ANA and 2-AG.

In vitro assessment of paraoxon effects on GABA uptake in rat hippocampal synaptosomes.

The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia

In this chapter, the anatomical, neurochemical, electrophysiological, and pharmacological bases that sustain the importance of the cannabinoid system in basal ganglia function are reviewed, attempting to present current information and future lines for research on the therapeutic potential of this system inBasal ganglia disorders.

Studies on the role of cannabinoids on dopamine transporter function: an optical method

PC results showed that differentiated PC12 cells had low expressions of the cannabinoid receptor 1 gene (CNR1), making this cell line unsuitable for this cannabinoid study, making it possible to assess transporter activity by quantitative fluorescence technique.

The role of the CB1 receptor in the regulation of sleep

  • E. Murillo-Rodríguez
  • Biology, Chemistry
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2008



Endocannabinoids in the central nervous system--an overview.

  • E. Fride
  • Biology, Chemistry
    Prostaglandins, leukotrienes, and essential fatty acids
  • 2002
The role of the endocannabinoid system in appetite stimulation in the adult organism, and perhaps more importantly, its critical involvement in milk ingestion and survival of the newborn, may not only further the understanding of the physiology of food intake and growth, but may also find therapeutic applications in wasting disease and infant's "failure to thrive".

Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission

In a rat model of Parkinson's disease induced by unilateral nigral lesion with 6-hydroxydopamine, the striatal levels of anandamide, but not that of the other endocannabinoid 2-arachidonoylglycerol, were increased, and inhibition of an andamide hydrolysis might represent a possible target to decrease the abnormal cortical glutamatergic drive in Parkinson’s disease.

Biphasic Effects of Cannabinoids on Acetylcholine Release in the Hippocampus: Site and Mechanism of Action

It is proposed that the in vivo observed biphasic effects ofCB1R agonists on hippocampal ACh release result from a differential, functional association of anatomicaly distinct subpopulations of CB1-Gi coupled receptors to neurotransmitter systems that have opposing effects on A cholinergic release.

Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism

Data show that anomalies in the endocannabinoid system induced by experimental parkinsonism are restricted to the striatum and can be reversed by chronic levodopa treatment, and suggest that inhibition of FAAH might represent a possible target to decrease the abnormal cortical glutamatergic drive in Parkinson's disease.

Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.

Assays of different central nervous system (CNS) regions demonstrated significant activity of cannabinoids in CB(1)(-/-) membranes from brain stem, cortex, hippocampus, diencephalon, midbrain, and spinal cord, but not basal ganglia or cerebellum.